The effect of the ergoline derivative, CU 32-085, on prolactin secretion in hyperprolactinemic women

J. S. Hesla, E. F. Rodman, M. E. Molitch, L. A. Goodman, R. J. Chang

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Twelve hyperprolactinemic women were administered the α aminoergoline derivative, CU 32-085 (Sandoz, Inc., East Hannover, NJ), in order to determine its effect on prolactin (PRL) secretion. The mean pretreatment serum PRL level was 145.0 ± 11.5 ng/ml. Significant declines of serum PRL occurred with total daily doses of CU 32-085 of 0.1 to 0.5 mg (P <0.001). The magnitude of response to therapy was dose-related. In six patients, PRL levels were reduced to less than 25 ng/ml; this effect lasted at least 24 hours after intake of a single dose. In the other six patients, the response was less dramatic. No subjects developed adverse cardiovascular side effects. The results of this study demonstrate that CU 32-085 exhibits a clinically significant dopaminomimetic action on PRL secretion in hyperprolactinemic women.

Original languageEnglish (US)
Pages (from-to)555-559
Number of pages5
JournalFertility and Sterility
Volume48
Issue number4
StatePublished - Jan 1 1987

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'The effect of the ergoline derivative, CU 32-085, on prolactin secretion in hyperprolactinemic women'. Together they form a unique fingerprint.

  • Cite this